A 30-year-old man with a long-standing psychotic disorder treated with olanzapine, diazepam and lofepramine was admitted to hospital after being found collapsed at home. There was some evidence of head trauma possibly related to falling out of bed. His mother reported that he was normally withdrawn but had not demonstrated any recent change in behaviour or shown signs of physical illness. There had been no recent changes to his medication.
A 30-year-old man with a long-standing psychotic disorder treated with olanzapine, diazepam and lofepramine was admitted to hospital after being found collapsed at home. There was some evidence of head trauma possibly related to falling out of bed. His mother reported that he was normally withdrawn but had not demonstrated any recent change in behaviour or shown signs of physical illness. There had been no recent changes to his medication.
He presented to the emergency department with a reduced level of consciousness and a Glasgow Coma Score (GCS) of 6 (E4, V1, M1). However, he seemed aware of his environment despite a lack of speech and motor response. Pupils were normal size and reactive. On physical examination, he was pyrexial with an axillary temperature of 40°C. His muscle tone and reflexes were normal. He was tachycardic with a pulse of 110 beats per minute (bpm), and normotensive.
Salient laboratory results were: serum glucose 78 mmol/L, white cell count 15 x 10 9 /L, creatinine 279 μmol/L, CRP 11 mg/L, corrected (for glucose) serum sodium 166 mmol/L and creatine kinase 4,000 IU/L. Urinalysis was positive for glucose and protein but negative for ketones. A venous blood gas showed a normal pH with lactate of 2.7 mmol/L.
The initial diagnosis in the emergency department was recorded as collapse secondary to diabetic ketoacidosis (DKA) and possible head injury. Cerebral infection was also considered and ceftriaxone plus acyclovir were started. He was resuscitated with an infusion of normal saline and insulin commenced at 6 IU/h. A CT scan of the brain was normal. He was transferred to the acute medical admissions unit without referral to critical care. Over the next 10 hours, his serum glucose concentration fell from 78 to 34 mmol/L and the corrected serum sodium rose from 164 to 175 mmol/L. His raised serum osmolality (400 mosm/L) and abnormal electrolytes were subsequently managed with appropriate fluid resuscitation.
A consultant physician reviewed him at this time (11 hours post admission) and considered hyperosmolar hyperglycaemic non-ketotic state to be more likely than DKA. He also raised the possibility of neuroleptic malignant syndrome (NMS) and referred the patient to critical care.
At review by the critical care team, he was noted to have a sinus tachycardia of 150 beats per minute and persistent pyrexia of 39.2°C. His GCS had improved to 11 (E 4, M 6, V 1) and he was moving limbs occasionally to command. The plantar reflexes were normal and muscle tone was not increased. There was no evidence of a compartment syndrome. He was transferred urgently to the intensive care unit (ICU) where he was resuscitated with cold intravenous fluids and surface cooling. Further blood tests revealed a significantly elevated creatine kinase at 14,570 IU/L, evidence of hepatic injury (AST peaked at 2,000 IU/L) and deranged clotting studies (INR 2.0, APTR 3.3). A 12-lead ECG confirmed a sinus tachycardia with no QT prolongation. The diagnosis at this stage remained uncertain, but acute drug poisoning by agents known to cause rhabdomyolysis and hyperthermia (such as MDMA) and neuroleptic malignant syndrome (NMS) were considered likely.
Five hours after his admission to the ICU, he became hypoxaemic requiring intubation and ventilation. Clinical examination prior to this deterioration now revealed marked upper limb rigidity although tone remained unaffected in the lower limbs. At this point, his creatine kinase had increased to 176,000 U/L and his acute kidney injury had worsened. He was anuric with a creatinine of 340 µmol/L. His nasopharyngeal temperature was 40°C. He was paralysed with atracurium and sedated to reduce muscle activity and heat Neuroleptic malignant syndrome: severe hyperthermia treated with endovascular cooling S Mathieu, S Hutchings, G Craig
We report a patient with neuroleptic malignant syndrome who presented with the characteristic features of altered mental state, hyperthermia, haemodynamic dysregulation, elevated creatine kinase and subsequently increased muscle rigidity. The hyperthermia was refractory to standard cooling techniques and dantrolene but was rapidly corrected using an endovascular cooling device. He recovered from this life-threatening condition but required ongoing renal replacement support following discharge from the intensive care unit.
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Case reports production. Dantrolene (1.5 mg/kg) was administered and renal replacement therapy instituted.
Despite these measures, his core temperature remained above 39°C an hour after commencing continuous venovenous haemofiltration and dantrolene administration. Other methods to achieve normothermia continued during this period. A PiCCO line was inserted into the left brachial artery, which confirmed a hyperdynamic circulation and registered a temperature of 41°C. At this point, an intravenous cooling device was inserted via the right femoral vein (ALSIUS ® Coolguard ® system). Using the device, the temperature decreased to 36°C, as did the tachycardia, from 165 to 125 bpm, within 30 minutes. His temperature was maintained at 37°C and intravascular cooling was stopped 41 hours later with removal of the device on the third day of his admission to intensive care. There was no rebound increase in temperature initially, although he subsequently developed a temperature of 38°C between days four and five. This coincided with a Staphylococcus aureus nosocomial pneumonia (isolated on nonbronchoscopic lavage), which was treated with tazocin and then de-escalated to flucloxacillin. His temperature settled within 24 hours of commencing antimicrobial therapy. A tracheostomy was inserted on day seven because of a slow respiratory wean. He was decannulated on day 20.
He was discharged from the ICU but required continual renal support and prolonged hospital stay for rehabilitation. His renal function has now recovered but he is left with residual leg weakness despite neuro-rehabilitation. An MRI of the spine has not demonstrated any abnormality to account for this. Further questioning of his mother revealed that he had taken multiple drug overdoses in the past although it remained unclear whether an overdose of anti-psychotic drugs had lead to this clinical presentation.
Discussion
NMS is a rare but serious complication of neuroleptic medications. The syndrome is characterised by fever, muscular rigidity, altered mental status, hyperthermia, and autonomic dysfunction. First described in 1967 as 'akinetic hypertonic syndrome,' NMS usually develops within two weeks of initiation of neuroleptic therapy or after a dose increase, although it can occur at any time. The heterogeneity and rarity of the syndrome can make recognition difficult, but with an associated mortality of 10-20%, 1 a high clinical suspicion for diagnosis and early supportive management are essential.
NMS is most often seen with the 'typical' high potency neuroleptic agents (eg haloperidol, fluphenazine). However, every class of neuroleptic drug has been implicated, including the low potency (eg chlorpromazine) and the newer 'atypical' antipsychotic drugs (eg clozapine, risperidone, olanzapine) as well as antiemetic drugs (eg metoclopramide, promethazine). Dopamine receptor blockade is considered to be the cause of NMS. Experimental blockade of dopamine in the striatum can cause rigidity, tremor and rhabdomyolysis, and in the hypothalamus temperature dysautoregulation and hyperthermia can occur. This is frequently accompanied by an intense hypermetabolic reaction in skeletal muscle that leads to rapidly evolving rigidity, extensive rhabdomyolysis and hyperkalaemia. 2 However, these signs are not invariable and may develop late leading to a delay in diagnosis, as in this case.
The most urgent therapeutic goal in NMS is reversal of hyperthermia and withdrawal of the causative agent. Commonly used methods include the use of cooling blankets, antipyretics, cooled intravenous fluids and ice packs. Additional pharmacological approaches include dantrolene for muscle relaxation and dopaminergic drugs (eg bromocriptine, amantadine), aimed at antagonising the effect of neuroleptic drugs at dopaminergic receptors. 3, 4 In our case, there was a delay in diagnosis and the severe hyperthermia was refractory to standard cooling measures plus dantrolene. We therefore inserted an endovascular heatexchange catheter (Icy TM catheter) and commenced endovascular cooling with the ALSIUS ® Coolguard ® system. This led to a dramatic reduction in core temperature, with normothermia achieved and sustained within thirty minutes of commencement (Figure 1) . The creatine kinase level peaked 48 hours later (Figure 2) . While there was a small rise in the patient' s temperature after stopping endovascular cooling, the creatine kinase level at this stage was falling. This pyrexia coincided with a positive microbiological growth from a nonbronchoscopic guided lavage and appeared to settle with appropriate antibiotic therapy.
Compared with a previous case report in the literature, 5 we Possible explanations for these differences include the fact that our patient was on continuous renal replacement therapy and received regular paracetamol; biochemical liver impairment in this case was transient. This may have contributed to the observation of less significant rebound pyrexia occurring after endovascular cooling was stopped. Also, it would appear that the pathological process might not have resolved in the previous case. As the authors suggest, a secondary worsening of rhabdomyolysis may then have occurred, explaining the subsequent rise in creatine kinase. Endovascular cooling is increasingly being used for neurological protection in patients who remain comatose but otherwise stable following an out-of-hospital cardiac arrest. 5, 6 However, this is only the second recorded case (and the first in the UK) of endovascular cooling successfully treating a patient with refractory hyperthermia in NMS despite a delay in diagnosis and referral to intensive care. 7, 8 We recommend the early use of endovascular cooling in these cases.
